Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease The Food and Drug ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval allows doctors to prescribe Ozempic specifically to lower the risk of kidney ...

The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug ...

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Singer Avery has been diagnosed with a condition that's thought to affect over 10 million Americans after she began using ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

It can be awkward (picture an hourlong gynecological exam, but friendlier), but it’s an underrated option for perimenopausal women with bladder, bowel, and sexual health struggles. Often, treatment is ...

The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...